Experts discuss the emerging role of SERDs in HR+ breast cancer

touchPANEL DISCUSSION for touchONCOLOGY Listen to leading experts review the latest advances in HR+ breast cancer, focusing on the management of specific patient subgroups and the potential impact of emerging oral, second-generation SERDs on patient standard of care. The experts Prof. Hope S Rugo – UCSF Comprehensive Cancer Center, San Francisco, CA, USA Dr Fatima Cardoso – Champalimaud Clinical Center, Lisbon, Portugal Dr Matti Aapro – Genolier Cancer Center, Genolier, Switzerland This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent educational grant from Sanofi Genzyme. This activity is provided by touchIME. For further information visit our website:  https://touchoncologyime.org/emerging-serds-for-treating-hr-positive-breast-cancer/